February 16, 2017 by Bill Hathaway Credit: Yale University <\/p>\n
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine. <\/p>\n
The median survival rate for patients with glioblastoma multiform (GBM) is only 15 months, but three separate genomic analyses of the tumor identified new mutations that allowed doctors to adjust treatment and keep the patient alive for over five years, through two recurrences of the cancer. <\/p>\n
\"We were able to identify the molecular profile at each recurrence,\" said Dr. Murat Gnel, chair and the Nixdorff-German Professor in the Department of Neurosurgery, researcher with Yale Cancer Center, and senior author of the paper. \"The molecular make-up of the cancer changed after each treatment and with time, but we were able to adjust treatments based on those profiles.\" <\/p>\n
For instance, the last genomic analysis revealed mutations of the cancerunder selective pressure from targeted therapieshad increased 30-fold, making the patient a good candidate for immunotherapy. Although there was an initial response, the cancer ultimately progressed. <\/p>\n
The researchers were able to extend the findings on this case to more than 100 other GBM cases, leading to the observation that most GBMs change their genomic profile during therapy. \"These findings have significant implications for precision treatment of these tumors\" said Dr. Zeynep Erson Omay, the first author of the study and a research scientist in neurosurgery. \"We now do a genetic analysis on every glioma surgically removed at Smilow Cancer Hospital during each recurrence or progression, comparing the molecular genomic profile to the original cancer to make treatment decisions.\" <\/p>\n
With new drugs available, there is hope that \"we will soon start to see real changes in patient outcomes,\" Gunel said. <\/p>\n
Explore further: Research team tracks twists and turns on the road to malignancy <\/p>\n
More information: E. Zeynep Erson-Omay et al. Longitudinal analysis of treatment-induced genomic alterations in gliomas, Genome Medicine (2017). DOI: 10.1186\/s13073-017-0401-9<\/p>\n
Journal reference: Genome Medicine <\/p>\n
Provided by: Yale University <\/p>\n
Gliomas can begin as benign growth in brain tissue but almost all eventually morph into malignant cancers called GBMs. Despite medical and surgical advances, GBMs remain one of the most deadly cancers in humans. <\/p>\n
Survival for patients with glioblastoma, an aggressive and deadly brain cancer, could be determined by the complexity of their tumor, according to researchers at the Translational Genomics Research Institute (TGen). <\/p>\n
Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some ... <\/p>\n
Nearly the entire genetic landscape of the most common form of brain tumor can be explained by abnormalities in just five genes, an international team of researchers led by Yale School of Medicine scientists report online ... <\/p>\n
Blood samples can be just as effective as invasive tissue biopsies in monitoring cancer and can help doctors better prescribe treatment, a study revealed Saturday. <\/p>\n
Next-generation sequencing for patients at UCSF Medical Center is prompting changes in brain tumor diagnoses for some children and a retooling of treatment plans in many cases. Sequencing is also providing valuable insights ... <\/p>\n
A new study that confirms the role of a protein called PAK4 in the movement and growth of pancreatic cancer cells could help researchers find new ways to tackle the disease. <\/p>\n
Researchers in Germany have discovered that a tumor suppressor protein thought to prevent acute myeloid leukemia (AML) can actually promote a particularly deadly form of the disease. The study, \"RUNX1 cooperates with FLT3-ITD ... <\/p>\n
Less aggressive cancers are known to have an intact genomethe complete set of genes in a cellwhile the genome of more aggressive cancers tends to have a great deal of abnormalities. Now, a new multi-year study of DNA ... <\/p>\n
An Australian-led international research effort has revealed that genetic changes normally linked to breast, colon and ovarian cancers could also drive a rare form of pancreatic cancer. <\/p>\n
Scientists at Winship Cancer Institute of Emory University have mapped a vast spider web of interactions between proteins in lung cancer cells, as part of an effort to reach what was considered \"undruggable.\" <\/p>\n
To understand what makes breast cancer spread, researchers are looking at where it lives - not just its original home in the breast but its new home where it settles in other organs. What's happening in that metastatic niche ... <\/p>\n
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more <\/p>\n
<\/p>\n
Read the rest here: February 16, 2017 by Bill Hathaway Credit: Yale University An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine. The median survival rate for patients with glioblastoma multiform (GBM) is only 15 months, but three separate genomic analyses of the tumor identified new mutations that allowed doctors to adjust treatment and keep the patient alive for over five years, through two recurrences of the cancer Continue reading
\nGenome analysis helps keep deadly brain cancer at bay for five years - Medical Xpress<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"